Autologous tumor-infiltrating lymphocyte (TIL) therapy expanded ex vivo; adoptive cellular immunotherapy delivering tumor-reactive T cells to mediate antigen-specific cytotoxicity and effector cytokine secretion.
Autologous tumor-infiltrating lymphocytes are isolated from the patient’s tumor, expanded ex vivo, and reinfused. These non-engineered T cells use their native TCRs to recognize tumor antigens presented by MHC on cancer cells, execute antigen-specific cytotoxicity (perforin/granzyme) and secrete effector cytokines (e.g., IFN-γ, TNF-α), enhancing antitumor immune responses.
Autologous TILs recognize tumor‑associated peptide–HLA class I complexes via their native TCRs and directly kill target cells through perforin/granzyme-mediated cytolysis (and death receptor pathways).
Autologous tumor-infiltrating lymphocyte (TIL) therapy expanded ex vivo; adoptive cellular immunotherapy delivering tumor-reactive T cells to mediate antigen-specific cytotoxicity and effector cytokine secretion.
Autologous tumor-infiltrating lymphocytes are isolated from the patient’s tumor, expanded ex vivo, and reinfused. These non-engineered T cells use their native TCRs to recognize tumor antigens presented by MHC on cancer cells, execute antigen-specific cytotoxicity (perforin/granzyme) and secrete effector cytokines (e.g., IFN-γ, TNF-α), enhancing antitumor immune responses.
Autologous TILs recognize HPV E6/E7 peptide–HLA class I via native TCRs and induce tumor cell death via perforin/granzyme-mediated cytolysis (and death receptor pathways).
Anti-CD20 monoclonal antibody causing B-cell depletion via ADCC, CDC, and apoptosis.
Chimeric anti-CD20 monoclonal IgG1 that binds CD20 on B cells and mediates B-cell depletion via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis.
Rituximab binds CD20 on B cells and induces killing via Fc-mediated ADCC (NK cells/macrophages), complement-dependent cytotoxicity, and direct apoptosis upon crosslinking.
Full-length bispecific monoclonal antibody that binds CD20 on B cells and CD3 on T cells to redirect and activate cytotoxic T-cell killing of malignant B cells.
Full-length bispecific monoclonal antibody that binds CD20 on B cells and CD3 on T cells, cross-linking T cells to CD20+ malignant B cells to activate T-cell receptor signaling and redirect cytotoxic T-cell killing of the tumor cells.
Odronextamab crosslinks CD3 on T cells with CD20 on target cells, activating T cells to kill CD20+ cells via redirected cytotoxicity (perforin/granzyme-mediated apoptosis).
Autologous tumor-infiltrating lymphocyte (TIL) adoptive cell therapy administered intravenously after lymphodepleting chemotherapy to mediate TCR-dependent cytotoxicity against tumor cells.
Autologous TILs expanded ex vivo are reinfused after lymphodepleting chemotherapy. They recognize patient-specific tumor antigens via TCR-MHC and kill tumor cells through perforin/granzyme-mediated cytotoxicity and cytokine release, with IL-2 supporting T-cell activation, proliferation, and persistence.
Adoptively transferred TILs recognize tumor-associated peptides presented on HLA-A/B/C via their TCR and kill target cells through perforin/granzyme-mediated cytolysis and Fas–FasL apoptosis, with IL-2 supporting T-cell function.